Literature DB >> 9083891

Modification of in vivo and in vitro TNF-alpha, IL-1, and IL-6 secretion by circulating monocytes during hyperbaric oxygen treatment in patients with perianal Crohn's disease.

G Weisz1, A Lavy, Y Adir, Y Melamed, D Rubin, S Eidelman, S Pollack.   

Abstract

Treatment of perianal inflammatory lesions in Crohn's disease (CD) is unsatisfactory and novel treatment modalities are pursued. We have recently reported a good clinical effect of hyperbaric oxygen (HBO) treatment in perianal CD. In the present study, seven patients with perianal CD were subjected to daily sessions of HBO in a multiplace hyperbaric chamber. Each patient received a total of 20 sessions during a time period of 1 month, and IL-1, IL-6, and TNF-alpha measurements were done several times during the initial sessions and after completing therapy. Pretreatment cytokine levels were elevated in patients compared to age-matched 10 normal controls. During the first 7 days of treatment, IL-1, IL-6, and TNF-alpha levels in supernatants of LPS-stimulated monocytes derived from patients' peripheral blood were decreased compared to pretreatment levels. Parallel measurements of serum IL-1 levels revealed an initial elevation and thereafter decreased levels, which remained low throughout the first week of HBO treatment. After completion of therapy, cytokine levels increased to pretreatment values. We conclude that alterations in secretion of IL-1, IL-6, and TNF-alpha may be related to the good clinical effect of HBO treatment in CD patients with perianal disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083891     DOI: 10.1023/a:1027378532003

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  29 in total

1.  Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4.

Authors:  E A Lobos; P Sharon; W F Stenson
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

Review 2.  Secretory products of macrophages.

Authors:  C F Nathan
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

Review 3.  The role of phagocytes in inflammatory bowel disease.

Authors:  A Hermanowicz; P R Gibson; D P Jewell
Journal:  Clin Sci (Lond)       Date:  1985-09       Impact factor: 6.124

4.  Effect of a single exposure to hyperbaric oxygen on blood mononuclear cells in human subjects.

Authors:  N Bitterman; H Bitterman; A Kinarty; Y Melamed; N Lahat
Journal:  Undersea Hyperb Med       Date:  1993-09       Impact factor: 0.698

5.  Arterial inflammatory-cell infiltration in Crohn's disease.

Authors:  S A Geller; A Cohen
Journal:  Arch Pathol Lab Med       Date:  1983-09       Impact factor: 5.534

6.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

7.  Recombinant human interleukin-8 is a potent activator of canine neutrophil aggregation, migration, and leukotriene B4 biosynthesis.

Authors:  M K Thomsen; C G Larsen; H K Thomsen; D Kirstein; T Skak-Nielsen; I Ahnfelt-Rønne; K Thestrup-Pedersen
Journal:  J Invest Dermatol       Date:  1991-02       Impact factor: 8.551

8.  Suppressive effect of hyperbaric oxygenation on immune responses of normal and autoimmune mice.

Authors:  K Saito; Y Tanaka; T Ota; S Eto; U Yamashita
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

9.  Effects of hyperoxia on phagocytosis.

Authors:  M Rister
Journal:  Blut       Date:  1982-09

10.  Healing of severe perineal and cutaneous Crohn's disease with hyperbaric oxygen.

Authors:  C E Brady; B J Cooley; J C Davis
Journal:  Gastroenterology       Date:  1989-09       Impact factor: 22.682

View more
  35 in total

1.  Effects of hyperoxia exposure on metabolic markers and gene expression in 3T3-L1 adipocytes.

Authors:  P Quintero; P González-Muniesa; D F García-Díaz; J A Martínez
Journal:  J Physiol Biochem       Date:  2012-04-26       Impact factor: 4.158

2.  Hyperbaric oxygen therapy and liver transplantation.

Authors:  Vijayaragavan Muralidharan; Chris Christophi
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

Review 3.  Hyperbaric Oxygen Therapy-A Novel Treatment Modality in Oral Submucous Fibrosis: A Review.

Authors:  M Ashwini Kumar; Besta Radhika; Nishanth Gollamudi; Satya Prakash Reddy; Uday Shankar Yaga
Journal:  J Clin Diagn Res       Date:  2015-05-01

Review 4.  Oxidative stress is fundamental to hyperbaric oxygen therapy.

Authors:  Stephen R Thom
Journal:  J Appl Physiol (1985)       Date:  2008-10-09

Review 5.  Hyperbaric oxygen: its mechanisms and efficacy.

Authors:  Stephen R Thom
Journal:  Plast Reconstr Surg       Date:  2011-01       Impact factor: 4.730

6.  The acute antinociceptive effect of hyperbaric oxygen is not accompanied by an increase in markers of oxidative stress.

Authors:  Shulin Liu; Donald Y Shirachi; Raymond M Quock
Journal:  Life Sci       Date:  2014-01-10       Impact factor: 5.037

7.  Hyperbaric oxygenation ameliorates indomethacin-induced enteropathy in rats by modulating TNF-alpha and IL-1beta production.

Authors:  Z Yang; J Nandi; J Wang; G Bosco; M Gregory; C Chung; Y Xie; X Yang; E M Camporesi
Journal:  Dig Dis Sci       Date:  2006-07-13       Impact factor: 3.199

8.  The relationship between N-acetylcysteine, hyperbaric oxygen, and inflammation in a rat model of acetaminophen-induced nephrotoxicity.

Authors:  Hakan Cermik; Mine Yavuz Taslipinar; Ibrahim Aydin; Mehmet Agilli; Fevzi Nuri Aydin; Fatma Ucar; Bilal Firat Alp; Mehmet Toygar; Esin Ozkan; Ertan Altayli; Tuncer Cayci
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

9.  Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages.

Authors:  R M Benson; L M Minter; B A Osborne; E V Granowitz
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

10.  Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial.

Authors:  Daniel A Rossignol; Lanier W Rossignol; Scott Smith; Cindy Schneider; Sally Logerquist; Anju Usman; Jim Neubrander; Eric M Madren; Gregg Hintz; Barry Grushkin; Elizabeth A Mumper
Journal:  BMC Pediatr       Date:  2009-03-13       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.